Alternatives to Evenity If You Can't Fill Your Prescription

Evenity (romosozumab) is a uniquely powerful osteoporosis treatment — its dual mechanism simultaneously builds new bone and reduces bone breakdown. But insurance barriers, prior authorization delays, cardiovascular contraindications, or simply not meeting eligibility criteria can leave some patients unable to access it. If you can't get Evenity, you have real options. Here's a complete look at the alternatives your doctor may consider.

Why Evenity May Not Be an Option for You

Some patients cannot use Evenity for medical reasons. Evenity carries an FDA boxed warning for risk of heart attack, stroke, and cardiovascular death. It should not be started in patients who have had a myocardial infarction (heart attack) or stroke within the preceding year. Patients with hypocalcemia (low blood calcium) must correct that first. Additionally, insurance denials, step therapy requirements, or the high list price (~$2,629/month) may make Evenity practically inaccessible.

Category 1: Anabolic Agents (Bone-Building Medications)

Like Evenity, these medications actively build new bone rather than just slowing bone loss.

Teriparatide (Forteo) — PTH Analog Anabolic Agent

Teriparatide (brand name Forteo, generic also available) is a parathyroid hormone analog that stimulates osteoblasts (bone-building cells). It's FDA-approved for postmenopausal women and men with osteoporosis at high fracture risk. Unlike Evenity's 12-month course, teriparatide is given as a daily subcutaneous injection for up to 24 months. It does not carry a cardiovascular boxed warning, making it an option for patients who have had a recent heart attack or stroke.

Key distinction from Evenity: Teriparatide is a self-injection (can be done at home with a pen device), while Evenity must be given by a healthcare provider. Generic teriparatide has become available, which may reduce costs significantly.

Abaloparatide (Tymlos) — PTHrP Analog Anabolic Agent

Abaloparatide (Tymlos) is a parathyroid hormone-related protein (PTHrP) analog approved for postmenopausal women and men with osteoporosis at high fracture risk. Like teriparatide, it's a daily self-injection for up to 24 months. Clinical studies suggest it may produce slightly lower rates of hypercalcemia compared to teriparatide. It also does not carry a cardiovascular boxed warning.

Category 2: Antiresorptive Agents (Slowing Bone Loss)

These medications don't build bone the way anabolics do, but they significantly slow bone loss and are often used after a course of anabolic therapy (like Evenity or teriparatide) to preserve gains.

Denosumab (Prolia) — Anti-RANKL Monoclonal Antibody

Denosumab (Prolia) is a subcutaneous injection given every 6 months by a healthcare provider. It inhibits RANKL, a protein that activates bone-resorbing cells (osteoclasts). Prolia is commonly prescribed after completing a 12-month Evenity course to preserve bone density gains — in fact, guidelines recommend following Evenity with an antiresorptive agent. Prolia is FDA-approved for postmenopausal women, men with osteoporosis, and patients on glucocorticoids.

Alendronate (Fosamax) — Oral Bisphosphonate

Alendronate is the most commonly prescribed bisphosphonate and a first-line treatment for most patients with osteoporosis. It's a once-weekly oral tablet available as a highly affordable generic. While it's not an anabolic agent (doesn't actively build bone), it significantly reduces spine and hip fracture risk. Many insurance plans require patients to try alendronate before approving Evenity — so some patients may have already been through this step.

Zoledronic Acid (Reclast) — IV Bisphosphonate

Zoledronic acid (Reclast) is an intravenous bisphosphonate infusion given once yearly. It's an excellent option for patients who cannot tolerate oral bisphosphonates (due to GI issues or difficulty staying upright 30 minutes after a pill). A single infusion provides 12 months of antiresorptive coverage, making adherence simpler.

How Do These Alternatives Compare to Evenity?

Evenity's dual anabolic-antiresorptive mechanism is unique — no other approved osteoporosis drug simultaneously builds bone AND reduces bone breakdown as powerfully. Clinical trials showed Evenity produced a 48% lower risk of new vertebral fracture compared to alendronate alone over 24 months (ARCH trial). That said, teriparatide and abaloparatide are also highly effective anabolic options, and bisphosphonates remain the workhorse of osteoporosis management for good reason — they're safe, proven, affordable, and effective for the majority of patients.

Talk to Your Doctor Before Switching

The right alternative depends on your fracture history, cardiovascular risk, bone mineral density scores, prior treatments, insurance coverage, and ability to self-inject. Never switch osteoporosis medications without guidance from your prescriber. If access to Evenity is the barrier, review our guide on why Evenity is hard to find for strategies to overcome insurance barriers before giving up on Evenity.

If you're trying to locate either Evenity or one of its alternatives at a pharmacy near you, medfinder can call pharmacies in your area to find which ones have it in stock.